A F Hottinger
Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.
Zeitlberger A, Putora P, Hofer S, Schucht P, Migliorini D, Hottinger A, Roelcke U, Läubli H, Spina P, Bozinov O, Weller M, Neidert M, Hundsberger T. Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis. J Neurooncol 2022; 158:359-367.
29.04.2022Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.
29.04.2022J Neurooncol 2022; 158:359-367
Zeitlberger A M, Putora Paul Martin, Hofer S, Schucht P, Migliorini D, Hottinger A F, Roelcke U, Läubli H, Spina P, Bozinov Oliver, Weller M, Neidert M, Hundsberger Thomas
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial
Wirsching H, Riklin C, Felsberg J, Roth P, Jones D, Pfister S, Rushing E, Abrey L, Reifenberger G, Held L, von Deimling A, Ochsenbein A, von Moos R, Caparrotti F, Tabatabai G, Roelcke U, Hottinger A, Jörger F, Schmid A, Plasswilm L, Schrimpf D, Mancao C, Capper D, Conen K, Hundsberger T, Weller M. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Ann Oncol 2018; 29:1423-1430.
01.06.2018Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial
01.06.2018Ann Oncol 2018; 29:1423-1430
Wirsching H-G, Riklin C, Felsberg J, Roth P, Jones D T W, Pfister S, Rushing E J, Abrey L, Reifenberger G, Held L, von Deimling A, Ochsenbein A, von Moos R, Caparrotti F, Tabatabai G, Roelcke U, Hottinger A F, Jörger F, Schmid A, Plasswilm Ludwig, Schrimpf D, Mancao C, Capper D, Conen K, Hundsberger Thomas, Weller M
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
Hottinger A, Bodmer A, Weber D, Schaller K, Mach N, Hundsberger T, Vargas M, Dunkel N, Squiban D, Espeli V, Ben Aissa A, Dietrich P. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer 2018
09.01.2018Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
09.01.2018Br J Cancer 2018
Hottinger A F, Bodmer A, Weber D C, Schaller K, Mach N, Hundsberger Thomas, Vargas M I, Dunkel N, Squiban D, Espeli V, Ben Aissa A, Dietrich P-Y
Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes
Hundsberger T, Weller M, Plasswilm L, Brügge D, Gross M, Pica A, Hermann E, Pesce G, Conen K, Dietrich P, Migliorini D, Roth P, Roelcke U, Hottinger A, Putora P. Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes. J Neurooncol 2016; 126:175-183.
01.01.2016Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes
01.01.2016J Neurooncol 2016; 126:175-183
Hundsberger Thomas, Weller M, Plasswilm Ludwig, Brügge Detlef, Gross M W, Pica A, Hermann E, Pesce G, Conen K, Dietrich P Y, Migliorini D, Roth P, Roelcke U, Hottinger A F, Putora Paul Martin
Behandlungsoptionen von Hirnmetastasen
Hundsberger T, Hottinger A. Behandlungsoptionen von Hirnmetastasen - Neue Optionen durch orale und molekulare Therapeutika. info@onkologie 2015; 5:5-7.
01.01.2015Behandlungsoptionen von Hirnmetastasen
01.01.2015info@onkologie 2015; 5:5-7
Hundsberger Thomas, Hottinger A F
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
Hottinger A, Bodmer A, Weber D, Schaller K, Mach N, Hundsberger T, Vargas M, Dunkel N, Squiban D, Espeli V, Aissa A, Dietrich P. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer 2014; 110:2655-2661.
01.05.2014Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
01.05.2014Br J Cancer 2014; 110:2655-2661
Hottinger A F, Bodmer A, Weber D C, Schaller K, Mach N, Hundsberger Thomas, Vargas M I, Dunkel N, Squiban D, Espeli V, Aissa A B, Dietrich P-Y